News

The patent entitled ‘Sustained-Release Bupropion and Bupropion/Mecamylamine Tablets’ discloses the formulation of pharmaceutical tablets containing sustained-release granules of bupropion HCl distributed in a sustained-release matrix. Horst Zerbe, president

Reportedly, the data from phase III programs conducted in MS, were included in the applications for regulatory approval submitted to the FDA and European Medicines Agency (EMEA), in

4SC-203 is a multi-target kinase inhibitor having selectivity profile against FLT3, FLT3 mutants and VEGF-Receptors in both in-vitro and in-vivo studies. FLT3 represents an attractive therapeutic target in

Dr Whaley Bishnoi and her team specialise in tunable nanoparticle sensors that look at local pH on an intercellular level. They use the Zetasizer Nano to measure the

The company claims that as a result of this approval, US healthcare professionals can conduct on-site chemistry analysis in less than 12 minutes for many types of conditions,

The company said that the trial 03-113 was a six-week, randomised, placebo-controlled trial in 490 patients, who had a fluorescein staining score of three in the central region

Reportedly, as part of a 2007 suit, Johnson & Johnson has alleged that Boston Scientific’s Promus Everolimus-Eluting Coronary Stent System infringed these four patents, known as the Wright/Falotico

The study conducted in 166 patients with the relapsing-remitting (RRMS) form of the disease, comprises an initial 24 week double-blind, placebo-controlled dosing period followed by a 24 week

In addition, the parties have executed a contract manufacturing services agreement under which BioLife will manufacture OriGen’s DMSO and DMSO/Dextran cryopreservation media products under sterile GMP conditions into